Dr. Hetty Carraway, MD

Dr. Carraway practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Carraway's NPI, 1457319717, was assigned on May 3, 2006. Dr. Carraway graduated from UMass Chan Medical School in 1998. Dr. Carraway holds Maryland license D57805.

Dr. Carraway's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Carraway's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Carraway to 2 more clinical labs, each named with a free account. Dr. Carraway's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carraway practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Carraway's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Carraway's licenses on file in 2 states: Maryland and Ohio.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, lymphoma and prostate cancer among the conditions Dr. Carraway treats.

CMS data shows 253 Medicare services from Dr. Carraway across 3 procedure codes in 2024, for 76 Medicare patients. Medicare paid $23,500 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. Carraway in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 62% have high cholesterol. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carraway's median patient age at 68, with 41% women.

In 2024, Dr. Carraway wrote 380 Medicare Part D claims for 52 patients. 69% of them were for generic drugs. CMS names the drug for 227 of them, across 10 drugs with 11 or more claims each, at $1,162,613 in total drug cost. In 2023, CMS named 167 claims across 9 drugs.

Dr. Carraway accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carraway as offering telehealth.

Dmand AI links 140 papers to Dr. Carraway, published from 2004 to 2025. 2017 was the busiest year, with 14. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and DNA Methylation. Dr. Carraway has published most often in Leukemia. Dr. Carraway's most frequent co-authors are Mikkael A. Sekeres, MD, Anjali S. Advani, MD and Amy Elizabeth Dezern, MD.

Dmand AI links Dr. Carraway to 8 clinical trials, 2 of them phase 1/2 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Leukemia, Myeloid. AbbVie sponsors the most, 2. Open Payments lists research payments to Dr. Carraway that name 2 trials.

CMS Open Payments shows 625 general payments to Dr. Carraway from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Celgene Corporation paid the most, $199,361. It also lists 28 research payments totaling $228,417 from 2019 to 2021, naming 2 clinical trials.

Dmand AI lists 4 awards for Dr. Carraway, most recently Selected Best Doctor in 2020.

Dr. Carraway graduated from UMass Chan Medical School in 1998. Dr. Carraway is a member of ASCO and ASH.

Dr. Carraway is in network with 19 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.